ホームPRRUF • OTCMKTS
add
Immutep Ltd
市場ニュース
財務情報
損益計算書
収益
純利益
| (AUD) | 2023年12月info | 前年比変化率 |
|---|---|---|
収益 | 105.54万 | 25.23% |
営業費用 | 240.11万 | 16.20% |
純利益 | -1061.41万 | -2.93% |
純利益率 | -1005.72 | 17.80% |
1 株当たりの収益 | — | — |
EBITDA | -1109.91万 | -8.28% |
実効税率 | — | — |
貸借対照表
総資産
負債総額
| (AUD) | 2023年12月info | 前年比変化率 |
|---|---|---|
現金および短期投資 | 1.04億 | 51.71% |
総資産 | 1.24億 | 43.92% |
負債総額 | 814.60万 | -12.60% |
純資産 | 1.16億 | — |
発行済み株式 | 11.89億 | — |
帳簿価格 | 1.83 | — |
総資産利益率 | -23.35% | — |
資本利益率 | -24.65% | — |
キャッシュ フロー
現金の純増減額
| (AUD) | 2023年12月info | 前年比変化率 |
|---|---|---|
純利益 | -1061.41万 | -2.93% |
営業キャッシュ フロー | -922.52万 | -54.83% |
投資キャッシュ フロー | -20.96万 | -607.90% |
財務キャッシュ フロー | -21.59万 | -278.22% |
現金の純増減額 | -984.14万 | -69.40% |
フリー キャッシュ フロー | -689.61万 | -2.37% |
概要
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
CEO
設立
2001
ウェブサイト
従業員数
19
